Jubilant life sciences, Company

Noida-based Jubilant Life Sciences on Tuesday announced that its subsidiary Jubilant Generics Ltd has entered into a non-exclusive licensing agreement with US-based Gilead Sciences to manufacture and sell anti-viral drug remdesivir, which is under clinical trials globally as a potential treatment of COVID-19 disease.The pact allows Jubilant to register, manufacture and sell remdesivir in 127 countries, including in India."We are very happy to strengthen our partnership with Gilead to license remdesivir, which, based on initial data, shows promise to be a potential therapy for COVID-19, a pandemic creating unprecedented health and economic crisis globally," Shyam S Bhartia, Chairman and Hari S. Bhartia, Co Chairman and Managing Director, Jubilant Life Sciences Limited said in a statement.Remdesivir is among the top WHO drugs currently under various trials to treat the deadly respiratory disease.Several additional clinical trials are currently ongoing to generate more data on the safety and efficacy of remdesivir as a treatment for COVID-19."We will be monitoring the clinical trials and regulatory approvals very closely and would be ready to launch the drug shortly after the required regulatory approvals. We also plan to produce the drug's Active Pharmaceutical Ingredient (API) in-house helping its cost effectiveness and consistent availability," said Jubilant Life Sciences in a stock exchange filing.Gilead Sciences said last week that it was negotiating long-term voluntary licences with several generic drugmakers in India and Pakistan to produce experimental antiviral drug remdesivir.The US Food & Drug Administration (FDA) has issued an emergency use authorisation for remdesivir in the treatment of Covid-19 patients.Union Health Minister Harsh Vardhan last week said that there is a confusion over the pricing and patent of experimental anti-viral drug remdesivir.The Health Ministry had recently said that it is examining remdesivir, which was used during the Ebola outbreak, as one protocol in the treatment for Covid-19.Gilead said it will provide appropriate technology transfers to facilitate remdesivir production, adding that it is in active discussions with the Medicines Patent Pool to licence remdesivir for developing countries.( With inputs from IANS )

Jubilant Life SciencesFOLLOW

Jubilant life sciences, Latest News

Gautam Buddh Nagar, Sep 24 A major fire broke out in a private company's office building in Sector ... ...

Jubilant Life Sciences has launched Remdesivir for injection under the brand name JUBI-R in Indian market at a price of Rs 4,700 per vial of 100 mg and said it will make the drug available to over 1,000 hospitals providing COVID-19 treatment through ...

TVS Motor Company registered a sales growth of 27 per cent in July 2020 with 252,744 units as against 198,387 units in June 2020. ...

Share India Securities Limited, one of India's leading hi- tech broking Company and financial service provider, announced strong financial results for the quarter and year ended March 31st 2020. ...

TVS Motor Company registered sales of 198,387 units in June 2020 as against 297,102 units registered in the month of June 2019. ...

The Annual General Meeting (AGM) of Reliance Industries Limited will be held on Wednesday through video conferencing. ...

The share price of Jubilant Life Sciences surged 5 per cent hitting upper circuit of Rs 429.95 per share on Wednesday after the company signed a deal with US-based Gilead Sciences Inc for production of Remdesivir to fight COVID-19. ...

Noida-based Jubilant Life Sciences on Tuesday announced that its subsidiary Jubilant Generics Ltd has entered into a non-exclusive licensing ... ...